Non-Animal Platform for Nanoparticle-Based Delivery Across the Blood-Brain Barrier Interface with Vehicle Evolution

The blood-brain barrier (BBB) is a major obstacle in treating diseases of the central nervous system (CNS) such as Parkinson’s, Alzheimer’s, schizophrenia and brain cancer, affecting 180 million Europeans with less than 5% of current candidate drugs effectively reaching the brain. NAP4DIVE strives to revolutionize the traditionally expensive and inefficient drug development for these diseases by establishing advanced non-animal alternatives for testing and predicting nanoparticle (NP)-based drug delivery across the human BBB. This approach aligns with EU and global initiatives to reduce animal testing and advance human-based biomedical research models.